Background: A novel phenomenon has been described by the phototrichogram: the emptiness of the follicle after teloptosis. We called this phenomenon kenogen, from the Greek ĸΕνóς, ‘empty’. Objective: To describe the kenogen phase in its details. Methods: Analysis of the existing literature. Results: The original observation in 2 women was confirmed in 10 balding and non-balding males studied for 14 years in whom kenogen lasted about 4 months increasing up to about 7 months and affecting 80% of all hair cycles. In 2 women with progressing androgenetic alopecia studied for 2 years, kenogen involved 22% of the hair follicles, lasting from 3 months to 1 year. In a prepubertal boy studied for 1 year, it involved 8% of hairs and lasted about 2 months. Conclusion: During kenogen, the hair follicle rests physiologically, but duration and frequency are greater in androgenetic alopecia, possibly accounting for baldness. In addition to the classical cycle, the hair follicle may follow an alternative route during which the telogen phase, not accompanied by a coincident new early anagen, ends with teloptosis leaving the follicle empty.

1.
Garcia SA: Beiträge zur Kenntnis des Haarwechsels bei menschlichen Embryonen und Neugeborenen. Morphol Arb 1891;1:137. Quoted by Pinkus F: Die normale Anatomie der Haut; in Jadassohn J (ed): Handbuch der Haut und Geschlechts-Krankheiten. Berlin, Springer, 1927, vol I, pp 1–378.
2.
Paus R: Principles of hair cycle control. J Dermatol 1998;25:793–780.
3.
Piérard-Franchimont C, Piérard GE: Teloptosis, a turning point in hair shedding biorhythms. Dermatology 2001;203:115–117.
4.
Van Neste DJJ, de Brouwer B, De Coster W: The phototrichogram: Analysis of some technical factors of variation. Skin Pharmacol 1994;7:67–72.
5.
Guarrera M, Ciulla MP: A quantitative evaluation of hair loss: The phototrichogram. J Appl Cosmetol 1986;4:61–66.
6.
Courtois M, Loussouarn G, Hourseau C, Grollier JF: Hair cycle and alopecia. Skin Pharmacol 1994;7:84–89.
7.
Courtois M, Loussouarn G, Hourseau C, Grollier JF: Ageing and hair cycles. Br J Dermatol 1995;132:86–93.
8.
Guarrera M, Rebora A: Anagen hairs may fail to replace telogen hairs in early androgenetic alopecia. Dermatology 1996;192:28–31.
9.
Rushton DH, Fenton DA: Quantitative evaluation of topical 5% minoxidil in the treatment of diffuse androgen-dependent alopecia (DADA) in females. Br J Dermatol 1992;127:423.
10.
Guarrera M, Cipriani C, Rebora A: Delayed telogen replacement in a boy’s scalp. Dermatology 1998;197:335–337.
11.
Ihm CW, Lee JY: Evaluation of daily hair counts. Dermatologica 1991;182:67.
12.
Kligman AM: Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch Dermatol 1961;83:175–197.
13.
Cotsarelis G, Sun T-T, Lavker RM: Label-retaining cells reside in the bulge area of pilosebaceous unit. Implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 1990;61:1329–1337.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.